Enhancer analysis of HER2+ cell lines SKBR-3 (ER-) and BT474m1 (ER+) in response to lapatinib and JQ1 and analysis of FOXA1 chromatin binding in SKBR-3 cells in response to lapatinib and JQ1 and impact of FOXA1 knockdown on BRD4 and MED1

SKBR-3 and BT474m1 HER2+ breast cancer cell lines were treated with lapatinib, JQ1, or lapatinib and JQ1 or (for SKBR-3) treated with siRNA pools (non-targeting control or FOXA1) prior to drug treatment before being used for ChIPseq (BRD4, MED1, H3K27Ac, or FOXA1 (for SKBR-3)) 36 experimental samples analyzed, 6 chromatin input control samples

本数据集以SKBR-3与BT474m1两种HER2阳性（HER2+）乳腺癌细胞系为研究材料。实验处理分为两类：其一，分别采用拉帕替尼（lapatinib）、JQ1单药或二者联合对细胞进行给药处理；其二，针对SKBR-3细胞系，在给药处理前转染小干扰RNA池（siRNA pools），设置非靶向对照（non-targeting control）与FOXA1靶向干扰两个对照组。所有处理完成的样本均用于染色质免疫共沉淀测序（ChIPseq），检测靶标包括BRD4、MED1及组蛋白H3第27位赖氨酸乙酰化修饰（H3K27Ac），SKBR-3组额外增加FOXA1靶标检测。本数据集共包含36个实验样本与6个染色质输入对照样本。